Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

At the Human Amyloid Imaging (HAI) meeting, held January 15-17, researchers focused on new techniques—all based on tau and ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

Researchers have developed a test that spots early signs of Alzheimer's disease. Rather than looking for amyloid-beta plaques ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...